LONDON — Lars Fruergaard Jørgensen, who led Novo Nordisk as it rode the boom of its obesity and diabetes medications to become one of the biggest players in pharma, only to see that success stall in recent months, is stepping down as CEO, the company said Friday.
Jørgensen, who’s worked at Novo for more than 30 years and has been CEO for eight, will continue in the position for a period “to support a smooth transition to new leadership,” the company said.
The search for the next CEO is ongoing.
Continue to STAT+ to read the full story…
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
